NICE guidance on AMD will not give advice on Avastin
This article was originally published in Scrip
The National Institute for Health and Care Excellence (NICE) has begun consulting on a draft guideline on treatments for age-related macular degeneration covering all therapies that are currently being used for wet AMD, including Novartis's Lucentis (ranibizumab), Roche's Avastin (bevacizumab), and Bayer's Eylea (aflibercept).
You may also be interested in...
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.
Russia’s new drug traceability system won’t now be implemented until July, but companies that are ready and able are being encouraged to put the system through its paces in order to flush out any glitches.